La filiale francese di Pfizer prevede il taglio di ulteriori posti di lavoro a causa della scadenza, a maggio 2012, del brevetto dell’anticolesterolo Tahor (atorvastatina – Torvast, Lipitor, Totalip, Xarator). According to the Ministry of Health, this measure would affect around 1,500 hospital ISFs, out of a total of 4,000 people. In 2009, Pfizer fired around 700 people in France, 600 of whom were ISF. Tahor's sales in 2010 reached €423 million, an increase of 3.2% compared to 2009.
(Les Echos Pag.21 – 14/09/2011, Les Echos online – 14/09/2011)